Background. A quadrivalent meningococcal glycoconjugate vaccine (MenACWY-CRM) is immunogenic in 4-dose infant or 2-dose toddler schedules. We report on persistence of bactericidal antibodies in each group at 60 months of age, and responses 1 month after a booster.
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Methods. In this phase IIIb, multi-center, open-label, controlled study (clinicaltrials.gov NCT01148017), subjects vaccinated as infants or toddlers were re-evaluated at 60 months of age, with age-matched vaccine-naïve controls. Bactericidal antibodies with human complement (hSBA) measured before and 1 month after booster are expressed as geometric mean titers (GMT) and proportions with seroprotective titers (≥ 8).
Results. We enrolled 131 infant-and 54 toddler-vaccinated subjects, and 50 controls. At 60 months titers had waned, but GMTs were higher in toddler-vaccinated than in infant-vaccinated, and both were higher than controls. Immune responses to another dose of MenACWY-CRM were higher in both prevaccinated groups, who displayed anamnestic responses. GMTs for serogroups A, C, W, and Y were 177, 206, 1706 and 1135 in infant-vaccinated, 356, 723, 1960 
